通过体外微电极阵列定义的β-粉样蛋白的神经毒性机制:一篇综述
Aoife O'Connell1, Leo Quinlan2, Andrea Kwakowsky1
1Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, University of Galway, Ireland.
Pharmacological research
|October 6, 2024
概括
微电极阵列显示,β-粉样蛋白在阿尔茨海默病模型中破坏神经元可塑性和网络功能. 这种功能性洞察力有助于理解神经毒性,并开发新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是β-粉样蛋白 (Aβ) 聚合,导致神经元损失和认知能力下降.
- 了解Aβ神经毒性的精确机制至关重要,因为AD的患病率越来越高.
- 微电极阵列 (MEAs) 提供了一种有价值的工具,用于在体外慢性,非侵入性监测神经元活动.
研究的目的:
- 审查和综合当前关于MEA使用的文献,以调查Aβ在阿尔茨海默氏病模型中的功能影响.
- 突出方法上的差异和该领域的研究状况.
- 为Aβ病理及其对神经元信号传递和可塑性的影响提供一个功能性视角.
主要方法:
- 对利用微电极阵列 (MEAs) 来记录神经元活动在各种体外阿尔茨海默氏病模型中的研究进行审查.
- 对调查β-粉样蛋白 (Aβ) 对自发和唤起的神经元活动,突触可塑性和网络连接性的影响的研究的分析.
- 基于MEA的研究中使用的不同实验模型,大脑区域和方法的比较.
主要成果:
- 尽管方法有所不同,但研究始终表明,Aβ抑制了突触可塑性并破坏了网络连接.
- Aβ对自发神经元活动的影响是复杂的,需要进一步研究.
- 证据支持Aβ在诱导渐进的神经毒性的作用,对神经元信号传递和可塑性产生不利影响.
结论:
- 微电极阵列是用于在阿尔茨海默病研究中功能性评估Aβ病理学的有效工具.
- MEA的发现弥合了细胞/网络病理和临床症状之间的差距,有助于治疗的发展.
- 来自MEA研究的功能性见解对于开发针对阿尔茨海默病的新型治疗干预措施至关重要.
更多相关视频
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.2K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
